British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend the indication of Arexvy (respiratory syncytial virus (RSV) ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

GSK is currently conducting clinical studies on Arexvy for expanded use in adults aged 18 to 49 years. Arexvy generated sales worth £590 million in 2024, while Abrysvo generated sales worth $755 ...

GSK has announced promising results for Arexvy, its respiratory syncytial virus (RSV) vaccine, showing a cumulative efficacy of 62.9% against RSV-related lower respiratory tract disease (RSV-LRTD ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through education and athlete stories.

GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults ...

GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market Nov. 07, 2024 2:53 PM ET Pfizer Inc. (PFE) Stock, GSK Stock, MRNA Stock By: Dulan Lokuwithana, SA News Editor 25 Comments Play (3min) ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...